// App-Quantinova.ai

: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev).

Researchers

Presenter

  • Linda Wu

Principal Investigators

  • Antonio D'Alessio

  • Hong Jae Chon

  • Masatoshi Kudo

  • Martin Schönlein

  • Johann von Felden

  • Brooke Wietharn

  • Samuel Phen

  • Bernhard Scheiner

  • Lorenz Balcar

  • Yi-Hsiang Huang

  • Tiziana Pressiani

  • Gianluca Masi

  • Abdul Rafeh Naqash

  • Dominik Bettinger

  • Arndt Vogel

  • Peter R Galle

  • Vince Gaillard

  • Celina Ang

Medical Centers

  • University Medical Center Mainz, Mainz, Germany

  • Taipei Veterans General Hospital, Taiwan

  • Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • University of Kansas School of Medicine, Kansas City, MO

  • Roche, Basel, Switzerland.

  • Department of Radiotherapy and Radio-Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

  • University of Pavia, Pavia, Italy

  • Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS, Rozzano, Italy

  • Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

  • Department of Medicine II: Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Medical Center - University of Freiburg, Freiburg, Germany

  • Hannover Medical School, Hannover, Germany

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan

  • Department of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, South Korea

  • Imperial College, London, United Kingdom

  • Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK

Locations

  • United Kingdom

  • Republic of South Korea

  • United States

  • Italy

  • Austria

  • Switzerland

  • Taiwan

  • Germany

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Neutrophil lymphocyte ratio

  • Platelet-lymphocyte ratio

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved